PharmaCyte Biotech (PMCB) Debt Ratio (2011 - 2021)
PharmaCyte Biotech (PMCB) posted quarterly Debt Ratio of 0.02 for Q1 2021, up 18.81% quarter-over-quarter from 0.01 in Q4 2020.
PharmaCyte Biotech (PMCB) Debt Ratio (2011 - 2021) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Debt Ratio for 6 consecutive years, with 0.02 the latest figure, recorded in Q1 2021.
- In Q1 2021, Debt Ratio changed N/A year-over-year to 0.02; the TTM figure through Jan 2021 stood at 0.02 (changed N/A YoY), while the FY2020 annual figure was 0.01, changed N/A from the prior year.
- Debt Ratio rose to 0.02 in Q1 2021 per PMCB's latest filing, from 0.01 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.02 in Q1 2021 and bottomed at 0.01 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.26 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.47 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.03 |
| 10 | PharmaCyte Biotech | 4.30 Mn | 4.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2021 | 0.02 |
| Oct 31, 2020 | 0.01 |
| Jul 31, 2020 | 0.02 |
| Apr 30, 2020 | 0.01 |
| Jan 31, 2014 | 0.00 |
| Oct 31, 2013 | 0.09 |
| Jul 31, 2013 | 0.12 |
| Apr 30, 2013 | 0.15 |
| Jan 31, 2013 | 0.29 |
| Oct 31, 2012 | 0.31 |
| Jul 31, 2012 | 0.33 |
| Apr 30, 2012 | 1.16 |
| Jan 31, 2012 | 1.32 |
| Oct 31, 2011 | 1.37 |
| Jul 31, 2011 | 1.50 |
| Apr 30, 2011 | 1.91 |